Immunic, Inc. (NASDAQ:IMUX - Free Report) - Leerink Partnrs boosted their Q2 2025 EPS estimates for shares of Immunic in a research note issued to investors on Wednesday, April 30th. Leerink Partnrs analyst F. Khurshid now forecasts that the company will earn ($0.16) per share for the quarter, up from their previous estimate of ($0.17). The consensus estimate for Immunic's current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Immunic's Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.69) EPS and FY2026 earnings at ($0.55) EPS.
A number of other research analysts also recently commented on IMUX. StockNews.com downgraded Immunic from a "hold" rating to a "sell" rating in a research note on Thursday, March 20th. B. Riley restated a "buy" rating and issued a $6.00 price objective on shares of Immunic in a report on Wednesday, April 16th. William Blair started coverage on shares of Immunic in a research note on Tuesday, March 25th. They issued an "outperform" rating for the company. D. Boral Capital restated a "buy" rating and set a $17.00 price target on shares of Immunic in a research note on Wednesday, April 30th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Immunic in a research note on Thursday. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $13.20.
Read Our Latest Analysis on IMUX
Immunic Stock Down 1.7 %
Immunic stock opened at $1.15 on Monday. Immunic has a 12 month low of $0.83 and a 12 month high of $2.11. The company's fifty day simple moving average is $1.08 and its 200-day simple moving average is $1.11. The stock has a market cap of $110.19 million, a P/E ratio of -0.93 and a beta of 1.73.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of IMUX. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Immunic by 90.0% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company's stock valued at $205,000 after acquiring an additional 96,894 shares during the period. Millennium Management LLC boosted its stake in Immunic by 480.6% during the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company's stock valued at $580,000 after purchasing an additional 479,846 shares during the period. Focus Partners Wealth grew its holdings in Immunic by 1.1% in the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company's stock valued at $2,168,000 after buying an additional 23,610 shares during the last quarter. Bridgeway Capital Management LLC grew its holdings in Immunic by 11.5% in the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock valued at $215,000 after buying an additional 22,200 shares during the last quarter. Finally, 683 Capital Management LLC increased its position in Immunic by 2.2% in the 4th quarter. 683 Capital Management LLC now owns 700,000 shares of the company's stock worth $700,000 after buying an additional 15,349 shares during the period. 51.82% of the stock is currently owned by institutional investors and hedge funds.
Immunic Company Profile
(
Get Free Report)
Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Immunic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.
While Immunic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
